ACRS - Company ID 0001557746
Aclaris Therapeutics, Inc. trades as ACRS. In its fiscal 2025 annual report the company posted revenue of $7.83M, down 58.2% from the prior year and net income of -$64.92M. This page tracks Aclaris Therapeutics, Inc. through 852 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years Aclaris Therapeutics, Inc.'s revenue grew from $1.68M to $7.83M, a compound annual growth rate of 21.2%. Net profit margin expanded from -4071.5% to -829.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-05 |
| Major company event | 8-K | 2026-04-28 |
| Insider trade | 4 | 2026-04-27 |
| SCHEDULE 13G/A | - | 2026-04-27 |
| Annual report to shareholders | ARS | 2026-04-23 |
The largest companies sharing Aclaris Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Aclaris Therapeutics, Inc. reported revenue of $7.83M for fiscal year 2025, a decrease of 58.2% year over year.
In its latest fiscal year Aclaris Therapeutics, Inc. reported a net loss of $64.92M.